BIOMX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.36 USD | -2.33% |
|
-11.76% | +28.57% |
| 18/04 | Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board | CI |
| 03/04 | Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 221.2 | 148.3 | 45.11 | 5.597 | 12.87 | 20.35 | - | - |
| Enterprise Value (EV) 1 | 221.2 | 148.3 | 45.11 | 5.597 | 12.87 | 20.35 | 20.35 | 20.35 |
| P/E ratio | -2.65 x | -4.91 x | -1.15 x | -0.2 x | -0.55 x | -1.47 x | -1.68 x | -1.71 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | -5.28 x | -1.37 x | -0.22 x | - | -0.61 x | -0.52 x | -0.44 x |
| EV / FCF | -1,35,97,200 x | - | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 22,835 | 23,241 | 28,196 | 29,977 | 45,974 | 55,220 | - | - |
| Reference price 2 | 9.685 | 6.380 | 1.600 | 0.1867 | 0.2800 | 0.3686 | 0.3686 | 0.3686 |
| Announcement Date | 26/03/20 | 31/03/21 | 30/03/22 | 29/03/23 | 03/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | -28.08 | -32.9 | -25.7 | - | -33.4 | -39.1 | -45.9 |
| EBIT 1 | -22.21 | -30.26 | -35.46 | -27.22 | -25.35 | -36.19 | -38.86 | -53.52 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -20.56 | -30.09 | -36.16 | -28.25 | -26.15 | -37.29 | -39.6 | -53.95 |
| Net income 1 | -20.6 | -30.1 | -36.23 | -28.32 | -26.17 | -37.29 | -39.6 | -53.95 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -3.660 | -1.300 | -1.390 | -0.9500 | -0.5100 | -0.2500 | -0.2200 | -0.2150 |
| Free Cash Flow | -16.26 | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 26/03/20 | 31/03/21 | 30/03/22 | 29/03/23 | 03/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -14.72 | -9.453 | -8.966 | -7.154 | -6.689 | -13.84 | -6.169 | -5.18 | -6.208 | -5.856 | -7.576 | - | -6.6 | -7.7 | -14.3 | -8.7 | -10.4 | - |
| EBIT 1 | -15.84 | -9.833 | -9.785 | -7.786 | -7.324 | - | -6.549 | -5.56 | -6.208 | -6.073 | -7.795 | -5.272 | -9.567 | -10.55 | - | -9.89 | -8.984 | -7.725 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.73 | -10.02 | -10.41 | -8.16 | -7.473 | -15.63 | -6.772 | -5.847 | -6.355 | -6.403 | -7.898 | -5.49 | -8.308 | -9.446 | -14.9 | -9.568 | -9.964 | -7.971 |
| Net income 1 | -15.74 | -10.03 | -10.46 | -8.169 | -7.482 | -15.65 | -6.78 | -5.886 | -6.361 | -6.411 | -7.906 | -5.491 | -8.308 | -9.446 | -14.9 | -9.568 | -9.964 | -7.971 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.6500 | -0.3700 | -0.3600 | -0.2700 | -0.2500 | -0.5300 | -0.2300 | -0.2000 | -0.2000 | -0.1200 | -0.1300 | -0.0800 | -0.1150 | -0.0650 | -0.1400 | -0.0650 | -0.0500 | -0.0400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/08/21 | 15/11/21 | 30/03/22 | 11/05/22 | 10/08/22 | 10/08/22 | 09/11/22 | 29/03/23 | 15/05/23 | 09/08/23 | 14/11/23 | 03/04/24 | - | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -16.3 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 3.68 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 26/03/20 | 31/03/21 | 30/03/22 | 29/03/23 | 03/04/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3686
USD
Average target price
3
USD
Spread / Average Target
+713.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.57% | 20.35M | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- PHGE Stock
- Financials BiomX Inc.